labetuzumab govitecan
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2018 (NCT03699332)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CEACAM5 binding agent
- DNA topoisomerase IINHIBITOR
DNA topoisomerase 1 inhibitor
- Carcinoembryonic antigen-related cell adhesion molecule 4Immunity, passive
CEACAM4 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- SN-38
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544923 ↗
Also known as
- labetuzumab govitecan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03699332 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2018 | Dutch Cancer Society, Radboud University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dutch Cancer Society | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Radboud University | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1